Get started
Author

Jimmie Huling Harvey

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
2012 · Srdan Verstovsek, Ruben A. Mesa, et al. · New England Journal of Medicine · 2,101
PDF
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
2017 · for the COMFORT-I investigators, Srdan Verstovsek, et al. · Journal of Hematology & Oncology · 431
PDF
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
2015 · S. Verstovsek, R. A. Mesa, et al. · Haematologica · 334
PDF
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
2013 · Ruben A. Mesa, Jason Gotlib, et al. · Journal of Clinical Oncology · 190
PDF
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
2013 · S. Verstovsek, R. A. Mesa, et al. · Haematologica · 170
PDF
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
2014 · Joachim von Pawel, Jimmie H. Harvey, et al. · Clinical Lung Cancer · 99
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis
2013 · Srdan Verstovsek, Ruben A. Mesa, et al. · British Journal of Haematology · 95
PDF
A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression
1998 · Roy A. Beveridge, John A. Miller, et al. · Cancer Investigation · 66
Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF).
2011 · S. Verstovsek, R. A. Mesa, et al. · Journal of Clinical Oncology · 40
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
2013 · R. A. Mesa, J.-J. Kiladjian, et al. · Haematologica · 39
PDF
Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
2012 · Srdan Verstovsek, Ruben A. Mesa, et al. · Blood · 34
Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I
2013 · Srdan Verstovsek, Ruben A. Mesa, et al. · Blood · 28
Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I
2011 · Srdan Verstovsek, Ruben A. Mesa, et al. · Blood · 23
Chemotherapy of pancreatic carcinoma
1984 · Jimmie H. Harvey, Philip S. Schein · World Journal of Surgery · 19
Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x109/L.
2012 · Moshe Talpaz, Solomon I. Hamburg, et al. · Journal of Clinical Oncology · 11
Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,
2011 · Ruben A. Mesa, Jason Gotlib, et al. · Blood · 10
Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
2012 · Srdan Verstovsek, Ruben A. Mesa, et al. · Journal of Clinical Oncology · 5
Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study
2016 · Hans Michael Kvasnicka, Juergen Thiele, et al. · Blood · 4
Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
2016 · Vikas Gupta, Srdan Verstovsek, et al. · Journal of Clinical Oncology · 2
Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)
2011 · Srdan Verstovsek, Ruben A. Mesa, et al. · Blood · 2
Works count: 20
Citation count: 3,703
H-index: 14
I10-index: 16
Year
Topic
Type